B lymphocytes as effector cells in the immunotherapy of cancer by Namm, Jukes P. et al.
Journal of Surgical Oncology 2012;105:431–435
REVIEW
B Lymphocytes as Effector Cells in the Immunotherapy of Cancer
JUKES P. NAMM, MD,1,2 QIAO LI, PhD,1 XIANGMING LAO, MD, PhD,1,3 DAVID M. LUBMAN, PhD,1
JINTANG HE, PhD,1 YASHU LIU, PhD,1 JIANHUI ZHU, PhD,1 SHUANG WEI, PhD,1 AND ALFRED E. CHANG, MD1*
1University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
2Department of Surgery, Loma Linda University, Loma Linda, California
3Sun Yat-sen University Cancer Center & State Key Laboratory of Oncology in Southern China, Guangzhou, China
Over the years, the role of B cells in the host immune response to malignancy has been overshadowed by our focus on T cells. Nevertheless,
B cells play important roles as antigen-presenting cells and in the production of antibodies. Furthermore, B cells can function as effector cells
that mediate tumor destruction on their own. This review will highlight the various functions of B cells that are involved in the host response
to tumor.
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INTRODUCTION
A simple deﬁnition of B lymphocytes is a population of cells that
express clonally diverse cell surface immunoglobulin (Ig) receptors
recognizing speciﬁc antigenic epitopes [1].The identiﬁcation of se-
rum gammaglobulin as the source of antibodies was the initiating
event for the discovery of antibody-producing cells. Plasma cells
were suggested as a source of antibody as early as 1948 [2]. Plasma
cells represent the terminally differentiated cells along the B cell
development/maturation pathway. The discovery of B cells occurred
in the mid-1960s simultaneously with the identiﬁcation of T cells.
Max Cooper and Robert Good described the functional distinction
between cells in the chicken bursa of Fabricius (B cells) responsible
for antibody production and cells that required an intact thymus (T
cells) for manifestation of delayed-type hypersensitivity responses
[3,4]. Shortly thereafter, B cells were found to express surface Ig
which could be used as markers to characterize these cells in the
normal state as well as leukemic state.
Besides the role of B cells in antibody production (aka humoral
immunity), B cells also mediate/regulate many other functions essen-
tial for immune homeostasis (Table I). Of signiﬁcant importance is
the antigen-presenting role of B cells in the initiation of T-cell im-
mune responses [5–8]. Depending upon the model system, B cells
have different requisite roles for antigen-presentation to T cells. The
congenital absence of B cells leads to abnormalities within the im-
mune system which includes a decrease in thymocyte numbers and
diversity, defects within spleen dendritic cell (DC) and T-cell com-
partments, an absence of Peyer patch organogenesis and follicular
DC networks, and an absence of macrophage subsets with decreased
chemokine expression [1]. Besides their role in the development of
the immune system, B cells can exert modulatory effects on the im-
mune system by the elaboration of cytokines [9–11]. These effects
can modulate T cell, DC, and antigen-presenting cell (APC) func-
tion; regulate lymphoid tissue organization and neogenesis; as well
as regulate wound healing and transplanted tissue rejection. B cells
can play a signiﬁcant role in infection and autoimmunity as regulato-
ry cells (Bregs) via the elaboration of suppressive cytokines, such as
IL-10, TGF-b, or IL-4 [10,12,13].
Abnormalities in B cell biology has resulted in clinicopathologic
conditions that underscore the important role of B cells in maintain-
ing normal physiology. Developmental blockade of B cells can lead
to signiﬁcant immunodeﬁciencies where Ig production is impaired
and susceptibility to infection is high [14–16]. Disruptions in the
regulation of B-cell reactivity can result in B cells capable of pro-
ducing high-afﬁnity effector antibodies that have autoreactivity. This
can result in pathological autoimmune conditions such as rheumatoid
arthritis. Dominant subclones of B cells with cytogenetic/molecular
genetic abnormalities can exist from all developmental stages of the
B-cell lineage that give rise to leukemias and lymphomas.
B CELLS IN CANCER IMMUNOLOGY
The role played by B cells in cancer immunology is complex and
somewhat controversial. Depending upon their state of activation, B
cells have had divergent roles on T-cell differentiation and effector
function. In tumor models, resting B cells have been reported to sup-
press T-cell-mediated antitumor immunity [17–24]. The mechanism
by which suppression is mediated by resting B cells on the antitumor
immune response is poorly understood. It appears to affect both
CD4þ [20] and CD8þ [22,24] T cells. Elaboration of IL-10 by B
cells [23] and interaction with Tregs (CD4þCD25þ cells) [24] have
been implicated as potential mechanisms in tumor models. However,
many of these studies have been performed using mice in which
the immune system develops in the complete absence of B cells.
These hosts are associated with a limited T-cell repertoire [25], lack
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follicular DCs and several macrophage populations [26], and have
enhanced IL-12 production by DC which can skew Th1 response
[27]. Hence, deﬁning the role of B cells during tumor immunity has
been difﬁcult. Using a wild-type host, DiLillo et al. [28] has recently
shown that B cells are required for optimal CD4þ and CD8þ immu-
nity induction. In their model, B cells were depleted in the wild-type
host using an anti-CD20 monoclonal antibody (mAb) rather than
using genetically B cell-deﬁcient hosts; and found that B16 melano-
ma tumor growth was increased in the B depleted hosts associated
with reduced effector-memory CD4þ and CD8þ immune T-cell
induction.
As opposed to resting B cells, several reports have indicated the
efﬁcacy of activated B cells in cellular immunotherapy of malignan-
cies. Many of these reports have been focused on how activated B
cells can be used as effective APCs for T-cell sensitization [29–35].
Activated B cells have been reported to enhance the ability to gener-
ate tumor-inﬁltrating lymphocytes in a culture system involving anti-
CD3 and IL-2 [36]. LPS-activated B cells bound to anti-CD3 has
been reported to mediate regression of B16 lung metastases
after adoptive transfer [37]. The mechanism by which the transferred
B-cell-mediated tumor destruction is unknown, but most likely
involved B–T cell interactions. The authors postulated that the acti-
vated B cells provided additional costimulatory signals to a host T-
cell response. Kawakami et al. [38] reported that the administration
of a DNA-based vaccine resulted in antitumor effects of established
murine tumors that was mediated by both T and B cells. In that
report, the role of B cells in mediating tumor regression was un-
known. There is a paucity of information about the ability of B cells
to directly kill tumor cells. The role of B cells in mediating tumor
destruction via tumor-speciﬁc antibody production is well established
and will be reviewed in a later section.
B CELLS AS EFFECTOR CELLS IN ADOPTIVE
IMMUNOTHERAPY
Recently, Li et al. [39] reported that tumor-primed B cells activat-
ed in vitro with anti-CD40 mAb and LPS-mediated tumor regression
upon adoptive transfer into mice bearing either lung metastases or
subcutaneous tumors [39]. These B cells were harvested from tumor-
draining lymph nodes (TDLN) of donor mice that had been inoculat-
ed with tumor cells in the ﬂanks. As shown in Figure 1, activated
TDLN B cells mediated signiﬁcant regression of pulmonary metasta-
ses [39]. The addition of TDLN T cells activated with anti-CD3 and
anti-CD28 mAb in the adoptive transfer resulted in even greater
tumor regression than either cell population alone (Fig. 1).
The observation that activated B cells alone can mediate tumor
regression in the adoptive immunotherapy of solid tumors is unique.
It was shown to be a consistent ﬁnding with three different tumor
histologies (i.e., sarcoma, melanoma, and breast cancer) [39,40]. One
potential mechanism by which activated B cells mediate tumor re-
gression is via tumor cell cytotoxicity. Li et al. [40] found that acti-
vated TDLN B cells can cause lysis of tumor cells in vitro as
measured by a standard LDH release assay. Using the 4T1 mammary
carcinoma murine tumor, 4T1 TDLN B cells activated with LPS and
anti-CD40 were able to lyse 4T1 tumor cells, and not irrelevant
Renca (renal cell carcinoma) or TSA (mammary adenocarcinoma)
tumor cells (Fig. 2). Hence, the B effector cells mediated tumor-
speciﬁc cytotoxicity. This unique phenomenon was evident in the
TABLE I. B Cell Properties
B-cell functions
Antibody production
Adaptive antibodies
Autoantibodies
Antigen presentation
T-cell costimulation
CD40, CD80, CD86
Cytokine production
Effector cytokines: IFN-g, IL-6
Regulatory cytokines: IL-10, TGF-b, IL-4
Physiological effects
Infection control
Lymphoid tissue organogenesis
Th1/Th2 cytokine balance
Dendritic cell regulation
Transplant rejection
Tumor immunity
Wound healing
Fig. 1. Activated B cells from tumor-draining lymph nodes
(TDLN) mediate tumor regression after adoptive transfer in mice
bearing 3-day established lung metastases. In these two separate
experiments groups of mice (n ¼ 6) received activated T cells alone,
B cells alone, or a combination of both. Mean number of pulmonary
metastases (SEM) at the end of the experiments are depicted in the
graphs. The combination of T and B cells was superior to all other
groups (Li et al. [39]).
Fig. 2. Activated B cells from TDLN can cause tumor cell cytoly-
sis in an immunologically speciﬁc fashion. 4T1 TDLN B cells were
secondarily activated with LPS/anti-CD40 and evaluated for cytotox-
icity using an LDH release assay. Activated B cells were admixed
with tumor cells at different effector:target (E:T) ratios and the
amount of killing was assessed. 4T1 TDLN B cells were able to kill
4T1 tumor cells, and not the irrelevant Renca or TSA tumors as
shown in these two separate experiments (Li et al. [40]).
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absence of antibody. The mechanism by which B effector cells lyse
tumor cells is presently unknown. In a separate report, Kemp et al.
[41] found that anti-CD40-activated human B cells were able to me-
diate tumor cell killing via a TRAIL/Apo-2L-dependent mechanism.
Another potential mechanism by which B effector cells mediate
tumor regression in adoptive immunotherapy is by presenting antigen
to the host cellular immune system. As noted above, B cells play an
important role as APCs for initiating T-cell immune response. It was
recently reported that the adoptive transfer of activated B cells spe-
ciﬁc for the 4T1 tumor into tumor-bearing hosts resulted in the in-
duction of systemic T-cell immunity to 4T1 that could be detected in
the peripheral blood and spleen [40]. This is illustrated in Figure 3
where groups of 4T1-bearing mice received activated B cells, IL-2
treatment, or no treatment; and splenocytes were harvested to moni-
tor for T-cell immunity to 4T1. As can be seen, IFN-g secretion was
observed from spleen cells obtained from mice that received activat-
ed B cells and not from mice that received IL-2 or no treatment. The
IFN-g response was speciﬁc in response to 4T1 tumor cells and not
to irrelevant TSA or MT-901 (mammary carcinoma) tumor cells.
B EFFECTOR CELLS AS PRODUCERS OF
ANTIGEN-SPECIFIC ANTIBODY
B cells have played a major role in the production of antibodies
speciﬁc to tumor-associated epitopes. Antibodies have played an in-
creasing role in therapeutic applications in the treatment of cancers
mainly by blockade of receptors important to tumor proliferation. An
example of this is bevacizumab (Avastin1) which is a recombinant
humanized monoclonal IgG1 antibody that binds to and inhibits the
biologic activity of human vascular endothelial growth factor
(VEGF). This antibody has been approved by the Food and Drug
Administration (FDA) for the treatment of several solid malignancies
(i.e., colorectal cancer, non-small cell lung cancer, glioblastoma, and
renal cell cancer).Another example is cetuximab (Erbitux1) which is
a humanized mAb that blocks the epidermal growth factor receptor
(EGFR) and is used in the treatment of colorectal cancer and head
and neck cancer. More recently, ipilimumab (Vervoy1) was ap-
proved for the treatment of melanoma. This humanized mAb binds
to CTLA-4, a molecule on activated T lymphocytes that downregu-
lates their function. By binding to CTLA-4, ipilimumab prevents
blockade of the immune T-cell response. The list of therapeutic mAb
that modulate cell function and can directly or indirectly lead to tu-
mor regression is growing.
Antibodies can also exert antitumor effects by other means. One
mechanism is by antibody-dependent cell-mediated cytotoxicity
(ADCC). This involves effector cell-mediated lysis of a target cell
that has been bound by a speciﬁc antibody. ADCC is mediated by
natural killer cells, neutrophils, T cells, and macrophages. Lopez
et al. [42] described the ability of B cells from tumor-bearing hosts,
but not normal non-tumor-bearing hosts to mediate tumor lysis via
ADCC. Another mechanism for tumor lysis involving antibody is
known as complement-dependent cytotoxicity (CDC). Antibody by
itself is ineffectual in the lysis of target cells. However, antibody of
the IgM and IgG classes can activate the complement system result-
ing in cell lysis. Rituximab (Rituxan1) is a humanized mAb that
binds to CD20 expressed on B cells. It was approved by the FDA for
the treatment of refractory B-cell lymphomas and is thought to medi-
ate B-cell antitumor effects via ADCC and CDC. Experimentally,
complement-ﬁxing tumor-speciﬁc antibodies can induce regression
of established human melanoma and breast tumors as reported using
in vivo models [31,32]. Furthermore, activated B effector cells have
been found to produce complement-ﬁxing antibody that can mediate
CDC. As shown in Figure 4, antibody produced by activated B cells
from D5 melanoma TDLN or MCA 205 sarcoma TDLN-mediated
tumor-speciﬁc CDC. Both ADCC and CDC may represent additional
mechanisms by which B effector cells mediate tumor regression in
an adoptive immunotherapy setting.
One additional advantage of developing B effector cells from
TDLN is the opportunity to identify novel tumor antigens. The
speciﬁcity of antibody generated by activated B effector cells dem-
onstrated in Figure 4 indicates the binding of antibody to unique
epitopes on the tumor cell surface. This is further illustrated in
Figure 5, where IgG2b antibody isolated from the supernatant of
MCA 205 TDLN B cells activated with LPS and anti-CD40
was examined for binding to MCA 205, D5, and Pan-02 (pancreatic
Fig. 3. Activated B cells induce tumor reactive T-cell responses in
tumor-bearing hosts. Mice-bearing 4T1 tumor were treated with acti-
vated B cells, IL-2, or no treatment. Spleens of the mice were har-
vested and splenic T cells activated in vitro. These activated splenic
T cells were tested for tumor reactivity by measuring IFN-g release
when mixed with irradiated tumor cells. Mice that received activated
4T1 TDLN B cells were found to have splenic T cells reactive to
4T1 tumor cells, and not to irrelevant tumor cells indicating the abil-
ity of activated B cells to present antigen to the secondary host (Li
et al. [40]).
Fig. 4. Activated TDLN B cells produce antibody that can mediate
complement-dependent cytotoxicity (CDC). Supernatants (Sup) from
activation cultures of D5 and MCA 205 TDLN B cells were tested
for their ability to mediate CDC in vitro. Pan-02 was used as an
irrelevant tumor cell control. As can be seen, the supernatants con-
tained antibodies that were able to speciﬁcally lyse the relevant tu-
mor targets (Li et al. [39]).
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carcinoma) tumor cells in vitro [39]. By immunoﬂuorescent
staining, the IgG2b antibody bound only to MCA 205 tumor cells.
Using immunoprecipitation techniques, antibody produced by tumor-
speciﬁc B effector cells can be used to bind to lysates of the tumor
cells and subsequently isolated by gel electrophoresis to identify
unique bands that may represent potential tumor-associated antigens.
An example of this is shown in Figure 6 where supernatants from
activated D5 melanoma B effector cells was used to bind to D5,
MCA 205, and Pan-02 tumor lysates, and the immune complex was
run in separate gel lanes. Supernatants from activated D5 melanoma
T effector cells were used as additional controls. The unique bands
associated with the D5 B cell supernatant lane represent unique D5
epitopes which can be further characterized by mass spectroscopy.
SUMMARY
The role of B cells in cancer immunotherapy has been overshad-
owed by the interest in developing T-cell-mediated cellular
responses. It is apparent that B cells can play a complementary role
in the host response against tumor. An overview of how B cells can
function in the therapeutic approach to cancer is depicted in
Figure 7. Under appropriate conditions, B cells can mediate direct
tumor cell killing independently or via antibody production. In
addition, there appears to be an effective synergy between B and T
cells to enhance the therapeutic efﬁcacy of cancer immunotherapy. B
cells can also exert regulatory functions via the release of cytokines.
The role of these Breg cells in the host tumor environment remains
to be deﬁned.
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